Reports actions taken by the Recombinant DNA Advisory Committee (RAC) to stiffen its guidelines on the reporting of deaths and adverse events in cases involving gene therapy patients. Why the branch of the National Institutes of Health (NIH) felt it needed to stiffen the guidelines; Response of the scientific community; Importance of protecting the commercial interest and the patient.